Compare TG & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | ORGO |
|---|---|---|
| Founded | 1988 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.4M | 239.3M |
| IPO Year | 1994 | 2016 |
| Metric | TG | ORGO |
|---|---|---|
| Price | $7.89 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 157.8K | ★ 878.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 151.06 | ★ 1600.00 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $800,821,000.00 | $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.27 |
| P/E Ratio | $23.47 | ★ N/A |
| Revenue Growth | 8.29 | ★ 17.04 |
| 52 Week Low | $6.25 | $1.54 |
| 52 Week High | $10.53 | $7.08 |
| Indicator | TG | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 28.03 |
| Support Level | $7.24 | $1.54 |
| Resistance Level | $8.20 | $2.64 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 31.84 | 23.00 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.